William Rushton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
William Rushton has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Jessica Rivera
Alabama Poison Information Center, Birmingham, AL, USA
5 shared publications - Jayamalathi Priyanka Vakkalanka
Department of Emergency Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA
3 shared publications - Erin Ryan
Banner University Medical Center Phoenix, Phoenix, USA
2 shared publications Julie Brown
Department of Emergency Medicine, University of Alabama-Birmingham, Birmingham, AL, USA
2 shared publicationsLewis S. Hardison
Division of Medical Toxicology, Department of Emergency Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA
2 shared publications- Michael Christopher Kurz
Section of Emergency Medicine, Department of Medicine, University of Chicago, IL (M.C.K.).
2 shared publications
Latest Publications
- 11 November 2026
- Published by Taylor & Francis in Clinical Toxicology
- p. 1-8
Withdrawal-related calls to a statewide poison control center: a ten-year review
- 11 November 2026
- Published by Taylor & Francis in Clinical Toxicology
- p. 1-8
Withdrawal-related calls to a statewide poison control center: a ten-year review
- Open Access
- 27 February 2026
- Published by Elsevier in JACEP Open
- Vol. 7 (2) , 100341
Tachycardia and Positive Amphetamine Screen are Associated With True Positive–Methamphetamine Exposures in Pediatric Patients
- 27 February 2026
- Published by Elsevier in JACEP Open
- Vol. 7 (2) , 100341
Open AccessTachycardia and Positive Amphetamine Screen are Associated With True Positive–Methamphetamine Exposures in Pediatric Patients
- 26 November 2025
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 100, 138-141
Calcium channel antagonists and point-of-care ultrasound: A case series
- 26 November 2025
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 100, 138-141
Calcium channel antagonists and point-of-care ultrasound: A case series
- 6 February 2025
- Published by Springer Nature in Journal of Medical Toxicology
- Vol. 21 (2) , 294-295
Commentary on Tianeptine Exposures Reported to United States Poison Centers, 2015–2023
- 6 February 2025
- Published by Springer Nature in Journal of Medical Toxicology
- Vol. 21 (2) , 294-295
Commentary on Tianeptine Exposures Reported to United States Poison Centers, 2015–2023
- Open Access
Antivenom Administration After Rattlesnake Envenoming in Arizona Does Not Directly Diminish Pain
The onset, progression, and severity of pain following rattlesnake envenomation are highly variable between patients. Pain can be severe and persistent, seemingly refractory to opioid analgesics. The ability of antivenom to directly relieve pain has not been well studied. We reviewed poison center charts of rattlesnake envenomations between 1 January 2018, and 31 December 2022. Demographic data as well as details of antivenom usage and pain severity were collected. Patients were coded in one of three categories: without pain (Pain 0), well controlled pain (Pain 1), and opioid refractory pain (Pain 2). A total of 289 patients met the inclusion criteria, with 140 receiving Anavip antivenom and 149 receiving Crofab. Patient characteristics were different between both cohorts. There were no significant differences in the number of Anavip vials used between the Pain 1 and Pain 2 groups. However, patients in the Crofab Pain 2 group received more antivenom compared to Pain 1. Importantly, Pain 3 patients were treated with the highest amount of antivenom in both the Crofab and Anavip cohorts. Despite the higher doses of antivenom used, these patients also experienced the greatest pain. These data suggest that antivenom alone may have minimal analgesic benefits.
Open AccessAntivenom Administration After Rattlesnake Envenoming in Arizona Does Not Directly Diminish Pain
The onset, progression, and severity of pain following rattlesnake envenomation are highly variable between patients. Pain can be severe and persistent, seemingly refractory to opioid analgesics. The ability of antivenom to directly relieve pain has not been well studied. We reviewed poison center charts of rattlesnake envenomations between 1 January 2018, and 31 December 2022. Demographic data as well as details of antivenom usage and pain severity were collected. Patients were coded in one of three categories: without pain (Pain 0), well controlled pain (Pain 1), and opioid refractory pain (Pain 2). A total of 289 patients met the inclusion criteria, with 140 receiving Anavip antivenom and 149 receiving Crofab. Patient characteristics were different between both cohorts. There were no significant differences in the number of Anavip vials used between the Pain 1 and Pain 2 groups. However, patients in the Crofab Pain 2 group received more antivenom compared to Pain 1. Importantly, Pain 3 patients were treated with the highest amount of antivenom in both the Crofab and Anavip cohorts. Despite the higher doses of antivenom used, these patients also experienced the greatest pain. These data suggest that antivenom alone may have minimal analgesic benefits.
- Open Access
- 27 November 2024
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 63 (1) , 16-22
After the bite: evaluating a specialized clinic for follow-up care for snake envenomation
Pit viper envenomation causes tissue damage that can persist for weeks to months despite antivenom. Many patients do not receive post-discharge care beyond testing for late coagulopathy and primary care follow-up. The aim of this report is to describe a snake envenomation patient cohort, complications, and management strategies after three years of operation of a specialized outpatient clinic offering post-discharge evaluation and wound care therapy. This was an observational study of patients treated in a newly established snakebite follow-up clinic from June 1, 2021 to November 30, 2023. Patient demographics, snake species, and hospital course were abstracted from poison center records. Persistent symptoms upon clinic evaluation were recorded as well as the therapies prescribed by the clinic wound care physicians. Of the 465 snake envenomations reported to the state poison center, 52 patients presented to the clinic. The median patient age was 29 years (range 5-88 years), and the majority (65.4%) were male. Antivenom was given during hospitalization in 92.3% of cases. Agkistrodon spp. envenomations (including Agkistrodon contortrix and Agkistrodon piscivorus) were most common (n = 33) with a smaller number of Crotalus horridus (n = 7) and 12 unidentified pit viper envenomations. Persistent edema (61.5%) and bullae (38.5%) were common at follow-up. Interventions provided included compression (38.5%), physical therapy referral (32.7%), tissue debridement (9.6%), and antibiotics (5.8%). Rates of edema and bullae were numerically higher in patients envenomated by Agkistrodon spp. compared to those envenomated by Crotalus horridus. In this primarily Agkistrodon spp.-envenomated cohort, persistent edema, wounds, and functional limitations were common in the post-discharge period. Our outpatient snake envenomation clinic leveraged the expertise of wound care physicians and the public health reach of the state poison center to address the significant morbidity seen on follow-up and provide interventions to facilitate recovery. This snake envenomation wound care clinic addressed a neglected aspect of pit viper envenomation by providing post-discharge management of enduring tissue damage and other complications.
- 27 November 2024
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 63 (1) , 16-22
Open AccessAfter the bite: evaluating a specialized clinic for follow-up care for snake envenomation
Pit viper envenomation causes tissue damage that can persist for weeks to months despite antivenom. Many patients do not receive post-discharge care beyond testing for late coagulopathy and primary care follow-up. The aim of this report is to describe a snake envenomation patient cohort, complications, and management strategies after three years of operation of a specialized outpatient clinic offering post-discharge evaluation and wound care therapy. This was an observational study of patients treated in a newly established snakebite follow-up clinic from June 1, 2021 to November 30, 2023. Patient demographics, snake species, and hospital course were abstracted from poison center records. Persistent symptoms upon clinic evaluation were recorded as well as the therapies prescribed by the clinic wound care physicians. Of the 465 snake envenomations reported to the state poison center, 52 patients presented to the clinic. The median patient age was 29 years (range 5-88 years), and the majority (65.4%) were male. Antivenom was given during hospitalization in 92.3% of cases. Agkistrodon spp. envenomations (including Agkistrodon contortrix and Agkistrodon piscivorus) were most common (n = 33) with a smaller number of Crotalus horridus (n = 7) and 12 unidentified pit viper envenomations. Persistent edema (61.5%) and bullae (38.5%) were common at follow-up. Interventions provided included compression (38.5%), physical therapy referral (32.7%), tissue debridement (9.6%), and antibiotics (5.8%). Rates of edema and bullae were numerically higher in patients envenomated by Agkistrodon spp. compared to those envenomated by Crotalus horridus. In this primarily Agkistrodon spp.-envenomated cohort, persistent edema, wounds, and functional limitations were common in the post-discharge period. Our outpatient snake envenomation clinic leveraged the expertise of wound care physicians and the public health reach of the state poison center to address the significant morbidity seen on follow-up and provide interventions to facilitate recovery. This snake envenomation wound care clinic addressed a neglected aspect of pit viper envenomation by providing post-discharge management of enduring tissue damage and other complications.
- Open Access
- 2 December 2023
- Published by Taylor & Francis in Toxicology Communications
- Vol. 7 (1)
Repeat antivenom administration following crotalidae immune F(ab’)2 antivenom in Agkistrodon species: a case series
- 2 December 2023
- Published by Taylor & Francis in Toxicology Communications
- Vol. 7 (1)
Open AccessRepeat antivenom administration following crotalidae immune F(ab’)2 antivenom in Agkistrodon species: a case series
- 17 March 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 386 (11) , 1099-1100
Snake Envenomation
To the Editor: In their excellent review of the management of snake envenomation, Seifert et al. (Jan. 6 issue)1 pay little attention to the importance of hospital follow-up. Despite aggressive treatment with early antivenom, patients may have lymphedema, decreased range of motion, progressing bullae, and coagulopathy that persist beyond their inpatient treatment.2,3 The North American Snakebite Registry has reported that 10.7% of snakebite victims with follow-up information had residual limb deficits. Even in this study, follow-up information was not available for approximately 40% of the patients, which emphasizes the lack of data regarding the true incidence of persistent venom sequelae.2 . . .
- 17 March 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 386 (11) , 1099-1100
Snake Envenomation
To the Editor: In their excellent review of the management of snake envenomation, Seifert et al. (Jan. 6 issue)1 pay little attention to the importance of hospital follow-up. Despite aggressive treatment with early antivenom, patients may have lymphedema, decreased range of motion, progressing bullae, and coagulopathy that persist beyond their inpatient treatment.2,3 The North American Snakebite Registry has reported that 10.7% of snakebite victims with follow-up information had residual limb deficits. Even in this study, follow-up information was not available for approximately 40% of the patients, which emphasizes the lack of data regarding the true incidence of persistent venom sequelae.2 . . .
- 16 June 2021
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 47 (4) , 411-413
Tianeptine: a new frontier in surveillance and understanding through social media
Interest in the abuse of tianeptine in the United States has been increasing over the past decade (1). The xenobiotic, which is known under the trade name internationally as Stablon or Coaxil, was ...
- 16 June 2021
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 47 (4) , 411-413
Tianeptine: a new frontier in surveillance and understanding through social media
Interest in the abuse of tianeptine in the United States has been increasing over the past decade (1). The xenobiotic, which is known under the trade name internationally as Stablon or Coaxil, was ...
- 4 July 2020
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 59 (3) , 256-259
Utilization of thromboelastograms in management of Crotalus adamanteus envenomation
Background: Crotalinae (pit viper) envenomations are frequently encountered in North American emergency departments. Cases can be complicated by ambiguity in initial species identification as well as timing and duration of current antivenin treatment. Recently, thromboelastography (TEG) has emerged as an enhanced real-time monitoring parameter for snake envenomations that may aid in management of venom-induced consumptive coagulopathy. Case: A 61-year-old snake handler presented with severe coagulopathy and hypofibrinogenemia following envenomation from her pet eastern diamondback rattlesnake (Crotalus adamanteus). Her coagulopathy transiently improved with Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) but would repeatedly rebound following cessation of antivenin over the next 10 days. Serial TEGs were successfully utilized to identify and corroborate fibrinolysis while predicting clot formation prior to routine coagulation studies. Discussion: Traditional coagulation parameters have not always been ideal when treating severe coagulopathy from pit viper envenomations and may not identify active fibrinolysis for several hours. In this case of C. adamanteus envenomation, TEG proved to be useful in demonstrating improvements in clotting function prior to standard laboratory measures, which further guided antivenin therapy.
- 4 July 2020
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 59 (3) , 256-259
Utilization of thromboelastograms in management of Crotalus adamanteus envenomation
Background: Crotalinae (pit viper) envenomations are frequently encountered in North American emergency departments. Cases can be complicated by ambiguity in initial species identification as well as timing and duration of current antivenin treatment. Recently, thromboelastography (TEG) has emerged as an enhanced real-time monitoring parameter for snake envenomations that may aid in management of venom-induced consumptive coagulopathy. Case: A 61-year-old snake handler presented with severe coagulopathy and hypofibrinogenemia following envenomation from her pet eastern diamondback rattlesnake (Crotalus adamanteus). Her coagulopathy transiently improved with Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) but would repeatedly rebound following cessation of antivenin over the next 10 days. Serial TEGs were successfully utilized to identify and corroborate fibrinolysis while predicting clot formation prior to routine coagulation studies. Discussion: Traditional coagulation parameters have not always been ideal when treating severe coagulopathy from pit viper envenomations and may not identify active fibrinolysis for several hours. In this case of C. adamanteus envenomation, TEG proved to be useful in demonstrating improvements in clotting function prior to standard laboratory measures, which further guided antivenin therapy.